Boehringer Ingelheim (BI) has formed a collaboration with the Sarah Cannon Research Institute, the research arm of Nashville, Tennessee-based Sarah Cannon,a global cancer institute of the Hospital Corporation of America, to bring together BI’s experience in cancer drug development and Sarah Cannon’s expertise in designing and optimizing clinical trials..

The joint clinical development program will study BI’s BI 754091 and BI 754111 monoclonal antibodies for the combination treatment of multiple cancers, including non-small cell lung cancer. BI 754091 and BI 754111 are immune checkpoint inhibitors. As both compounds interact with the immune system at different points, the combination treatment approach is expected to result in better anti-tumor response, potentially leading to improved outcomes for patients, according to BI. Following preliminary findings, the collaboration could be expanded beyond the initial research focus.

Source: Boehringer Ingelheim